The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat

Epilepsy Research

Volumn 85, Issue 1, 2009, Pages 96-106

  Large, Charles H ^a   Kalinichev, Mikhail ^b   Lucas, Adam ^b   Carignani, Corrado ^a   Bradford, Andrea ^b   Garbati, Nicoletta ^a   Sartori, Ilaria ^a   Austin, Nigel E ^b   Ruffo, Alberto ^a   Jones, Declan N C ^b   Alvaro, Giuseppe ^a   Read, Kevin D ^c  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Anticonvulsant; JZP 4; Lamotrigine; Pharmacokinetics; Sodium channel; Valproate

Indexed keywords

2 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL] 1,7 DIAZASPIRO[4.4]NONAN 6 ONE; 2 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL] 7 METHYL 1,7 DIAZASPIRO[4.4]NONAN 6 ONE; 5 [(4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL]PROLINAMIDE; 5 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL] 2 METHYLPROLINAMIDE; ANTICONVULSIVE AGENT; GW 273225; GW 273293; GW 286103; GW 356194; LAMOTRIGINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; ELECTRIC SHOCK; GRAND MAL SEIZURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIPOPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT;

ANIMALS; ANTICONVULSANTS; BIOPHYSICS; CELL LINE, TRANSFORMED; DIALYSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; ELECTROSHOCK; HUMANS; MALE; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; RATS; SEIZURES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TRANSFECTION; TRIAZINES;

EID: 67349119869     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.02.018     Document Type: Article

References (29)

1. Bean B.P., Cohen C.J., and Tsien R.W. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 81 (1983) 613-642
2. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
3. Bialer M., Twyman R.E., and White H.S. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. 5 (2004) 866-872
4. Castel-Branco M.M., Falcao A.C., Figueiredo I.V., and Caramona M.M. Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam. Clin. Pharmacol. 19 (2005) 669-675
5. Catterall W.A. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. 79 (1999) 441-456
6. Clare J.J., Tate S.N., Nobbs M., and Romanos M.A. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 5 (2000) 506-520
7. Foreman M.M., Hanania T., Stratton S.C., Wilcox K.S., White H.S., Stables J.P., and Eller M. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol. Biochem. Behav. 89 (2008) 523-534
8. Kalvass J.C., and Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 23 (2002) 327-338
9. Kimball A.W., Burnett Jr. W.T., and Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat. Res. 7 (1957) 1-12
10. Kuo C.C. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol. Pharmacol. 54 (1998) 712-721
11. Kuo C.C., and Bean B.P. Na+ channels must deactivate to recover from inactivation. Neuron 12 (1994) 819-829
12. Kuo C.C., and Bean B.P. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol. Pharmacol. 46 (1994) 716-725
13. Kuo C.C., Huang R.C., and Lou B.S. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol. Pharmacol. 57 (2000) 135-143
14. Kuo C.C., and Lu L. Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br. J. Pharmacol. 121 (1997) 1231-1238
15. Liu G., Yarov-Yarovoy V., Nobbs M., Clare J.J., Scheuer T., and Catterall W.A. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 44 (2003) 413-422
16. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
17. Loscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
18. Messenheimer J.A. Lamotrigine. Epilepsia 36 Suppl. 2 (1995) S87-S94
19. Niespodziany I., Klitgaard H., and Margineanu D.G. Is the persistent sodium current a specific target of anti-absence drugs?. Neuroreport 15 (2004) 1049-1052
20. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
21. Spadoni F., Hainsworth A.H., Mercuri N.B., Caputi L., Martella G., Lavaroni F., Bernardi G., and Stefani A. Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons. Neuroreport 13 (2002) 1167-1170
22. Summerfield S.G., Read K., Begley D.J., Obradovic T., Hidalgo I.J., Coggon S., Lewis A.V., Porter R.A., and Jeffrey P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322 (2007) 205-213
23. Taverna S., Mantegazza M., Franceschetti S., and Avanzini G. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res. 32 (1998) 304-308
24. Vreugdenhil M., van Veelen C.W., van Rijen P.C., Lopes da Silva F.H., and Wadman W.J. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res. 32 (1998) 309-320
25. Vreugdenhil M., and Wadman W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 40 (1999) 1512-1522
26. Whitaker W.R., Faull R.L., Dragunow M., Mee E.W., Emson P.C., and Clare J.J. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus. Neuroscience 106 (2001) 275-285
27. White H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 Suppl. 7 (2003) 2-8
28. White H.S., Smith M.D., and Wilcox K.S. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol. 81 (2007) 85-110
29. Xie X., Lancaster B., Peakman T., and Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch. 430 (1995) 437-446